Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy wins approval for generic analgesics

India-headquartered Ranbaxy Pharmaceuticals (RPI) has won FDA approval to manufacture and market two analgesic drugs.

India-headquartered Ranbaxy Pharmaceuticals (RPI) has won FDA approval to manufacture and market two analgesic drugs.

The FDA approval permits Ranbaxy to produce different dosages of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain.

The approved drugs are bio-equivalent copies of Norco, Vicodin and Lortab, the annual market sales of which were USD 391m.

Jim Meehan, vice-president of sales and marketing for RPI, said: "These approvals further expand our product portfolio of affordable generic alternatives and will be launched in a November 2007 time period."

21st August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics